These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 34560776

  • 1. Deep learning-driven scaffold hopping in the discovery of Akt kinase inhibitors.
    Wang Z, Ran T, Xu F, Wen C, Song S, Zhou Y, Chen H, Lu X.
    Chem Commun (Camb); 2021 Oct 12; 57(81):10588-10591. PubMed ID: 34560776
    [Abstract] [Full Text] [Related]

  • 2. Discovery of pyrrolopyrimidine inhibitors of Akt.
    Blake JF, Kallan NC, Xiao D, Xu R, Bencsik JR, Skelton NJ, Spencer KL, Mitchell IS, Woessner RD, Gloor SL, Risom T, Gross SD, Martinson M, Morales TH, Vigers GP, Brandhuber BJ.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5607-12. PubMed ID: 20810279
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Application of deep generative model for design of Pyrrolo[2,3-d] pyrimidine derivatives as new selective TANK binding kinase 1 (TBK1) inhibitors.
    Song S, Tang H, Ran T, Fang F, Tong L, Chen H, Xie H, Lu X.
    Eur J Med Chem; 2023 Feb 05; 247():115034. PubMed ID: 36603506
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
    Yu X, Xu J, Shen Y, Cahuzac KM, Park KS, Dale B, Liu J, Parsons RE, Jin J.
    J Med Chem; 2022 Feb 24; 65(4):3644-3666. PubMed ID: 35119851
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2).
    Hawkinson JE, Sinville R, Mudaliar D, Shetty J, Ward T, Herr JC, Georg GI.
    ChemMedChem; 2017 Nov 22; 12(22):1857-1865. PubMed ID: 28952188
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity.
    Liu Y, Zhang Z, Ran F, Guo K, Chen X, Zhao G.
    Bioorg Chem; 2020 Apr 22; 97():103671. PubMed ID: 32120074
    [Abstract] [Full Text] [Related]

  • 12. Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.
    Fischer T, Krüger T, Najjar A, Totzke F, Schächtele C, Sippl W, Ritter C, Hilgeroth A.
    Bioorg Med Chem Lett; 2017 Jun 15; 27(12):2708-2712. PubMed ID: 28478927
    [Abstract] [Full Text] [Related]

  • 13. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.
    de Vicente J, Lemoine R, Bartlett M, Hermann JC, Hekmat-Nejad M, Henningsen R, Jin S, Kuglstatter A, Li H, Lovey AJ, Menke J, Niu L, Patel V, Petersen A, Setti L, Shao A, Tivitmahaisoon P, Vu MD, Soth M.
    Bioorg Med Chem Lett; 2014 Nov 01; 24(21):4969-75. PubMed ID: 25262541
    [Abstract] [Full Text] [Related]

  • 14. Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
    Arcari JT, Beebe JS, Berliner MA, Bernardo V, Boehm M, Borzillo GV, Clark T, Cohen BD, Connell RD, Frost HN, Gordon DA, Hungerford WM, Kakar SM, Kanter A, Keene NF, Knauth EA, Lagreca SD, Lu Y, Martinez-Alsina L, Marx MA, Morris J, Patel NC, Savage D, Soderstrom CI, Thompson C, Tkalcevic G, Tom NJ, Vajdos FF, Valentine JJ, Vincent PW, Wessel MD, Chen JM.
    Bioorg Med Chem Lett; 2013 May 15; 23(10):3059-63. PubMed ID: 23566514
    [Abstract] [Full Text] [Related]

  • 15. Development of pyridopyrimidines as potent Akt1/2 inhibitors.
    Wu Z, Hartnett JC, Neilson LA, Robinson RG, Fu S, Barnett SF, Defeo-Jones D, Jones RE, Kral AM, Huber HE, Hartman GD, Bilodeau MT.
    Bioorg Med Chem Lett; 2008 Feb 15; 18(4):1274-9. PubMed ID: 18249537
    [Abstract] [Full Text] [Related]

  • 16. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
    Brasca MG, Nesi M, Avanzi N, Ballinari D, Bandiera T, Bertrand J, Bindi S, Canevari G, Carenzi D, Casero D, Ceriani L, Ciomei M, Cirla A, Colombo M, Cribioli S, Cristiani C, Della Vedova F, Fachin G, Fasolini M, Felder ER, Galvani A, Isacchi A, Mirizzi D, Motto I, Panzeri A, Pesenti E, Vianello P, Gnocchi P, Donati D.
    Bioorg Med Chem; 2014 Sep 01; 22(17):4998-5012. PubMed ID: 25009002
    [Abstract] [Full Text] [Related]

  • 17. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
    Cheng H, Nair SK, Murray BW, Almaden C, Bailey S, Baxi S, Behenna D, Cho-Schultz S, Dalvie D, Dinh DM, Edwards MP, Feng JL, Ferre RA, Gajiwala KS, Hemkens MD, Jackson-Fisher A, Jalaie M, Johnson TO, Kania RS, Kephart S, Lafontaine J, Lunney B, Liu KK, Liu Z, Matthews J, Nagata A, Niessen S, Ornelas MA, Orr ST, Pairish M, Planken S, Ren S, Richter D, Ryan K, Sach N, Shen H, Smeal T, Solowiej J, Sutton S, Tran K, Tseng E, Vernier W, Walls M, Wang S, Weinrich SL, Xin S, Xu H, Yin MJ, Zientek M, Zhou R, Kath JC.
    J Med Chem; 2016 Mar 10; 59(5):2005-24. PubMed ID: 26756222
    [Abstract] [Full Text] [Related]

  • 18. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.
    Skerratt SE, Andrews M, Bagal SK, Bilsland J, Brown D, Bungay PJ, Cole S, Gibson KR, Jones R, Morao I, Nedderman A, Omoto K, Robinson C, Ryckmans T, Skinner K, Stupple P, Waldron G.
    J Med Chem; 2016 Nov 23; 59(22):10084-10099. PubMed ID: 27766865
    [Abstract] [Full Text] [Related]

  • 19. Recent progress towards clinically relevant ATP-competitive Akt inhibitors.
    Huck BR, Mochalkin I.
    Bioorg Med Chem Lett; 2017 Jul 01; 27(13):2838-2848. PubMed ID: 28506751
    [Abstract] [Full Text] [Related]

  • 20. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
    Yap TA, Walton MI, Hunter LJ, Valenti M, de Haven Brandon A, Eve PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman P, Collins I, Garrett MD.
    Mol Cancer Ther; 2011 Feb 01; 10(2):360-71. PubMed ID: 21191045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.